Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Huamao Mark Lin

6PUBLICATIONS

8CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cross-sectional analysisRheumatology and arthritis

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 11, 2022

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.

Karen L Reckamp, Huamao M Lin, Holly Cranmer

|May 27, 2022

Non-small cell lung cancer with <i>EGFR</i> exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes.

Christina Soeun Kwon, Huamao M Lin, Victoria Crossland

|May 24, 2022

Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancer.

Karen L Reckamp, Huamao M Lin, Holly Cranmer

|Apr 30, 2020

Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

Huamao M Lin, Xiaoyun Pan, Peijie Hou

|May 25, 2019

Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.

Ariane K Kawata, William R Lenderking, Olabimpe R Eseyin

|Jan 06, 2018

Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.

Parameswaran Hari, Huamao Mark Lin, Carl V Asche

Pageof 1

Frequent Collaborators

2 joint publications

Karen L Reckamp

2 joint publications

Holly Cranmer

2 joint publications

Stephen Kay

2 joint publications

Sanjay Popat

1 joint publications

Allie Cichewicz

1 joint publications

Anna Forsythe

1 joint publications

Jinma Ren

1 joint publications

Vaishali Sanchorawala

Frequent Collaborators

2 joint publications

Karen L Reckamp

2 joint publications

Holly Cranmer

2 joint publications

Stephen Kay

2 joint publications

Sanjay Popat

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on : Sep 08, 2023

See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on : Sep 08, 2023

See more related videos